BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MIM-D3: Phase II started

Mimetogen began a double-blind, placebo-controlled Phase II trial to evaluate 1 drop of MIM-D3 given twice daily in...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >